2016-2017 influenza vaccine

The 2016-2017 influenza vaccine refers to the seasonal formulation designed to protect against the influenza virus strains predicted to circulate during the 2016-2017 season. In the context of the Emory University study (NCT02876159), the specific vaccine used was Fluzone, a quadrivalent inactivated influenza vaccine (QIV) manufactured by Sanofi Pasteur. It contains inactivated hemagglutinin (HA) and neuraminidase (NA) proteins from four strains: two influenza A strains (H1N1 and H3N2) and two influenza B strains (Victoria and Yamagata lineages). The vaccine is administered via intramuscular injection and works by eliciting a humoral and cellular immune response, primarily through the production of antibodies against the HA protein, to prevent seasonal influenza infection.

Brand names

FluzoneFluarixFluLavalAfluria

Other names

2016-2017 seasonal influenza vaccinequadrivalent inactivated influenza vaccineQIV